CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapyAmelie Franken, Diether Lambrechts, Orian Bricard et al.|Immunity|2024Cited by 108
Inflammation-Based Index and <sup>68</sup>Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOCElin Pauwels, Christophe M. Deroose, Sofie Van Binnebeek et al.|Journal of Nuclear Medicine|2019Cited by 44
Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine TumorsVincent Vandecaveye, Christophe M. Deroose, Raphaëla C. Dresen et al.|Radiology Imaging Cancer|2022Cited by 7
Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.Michel Bila, Paul M. Clément, Amelie Franken et al.|Journal of Clinical Oncology|2023Cited by 2